Psoriasis Update: Can We Finally Say Cure?

Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland, shares data from the Knock-out study showing that high induction doses of risankizumab (Skyrizi, AbbVie) can put patients with moderate-to-severe plaque psoriasis into long-term remission.